Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage?
Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage?
Introduction.? Some physicians prescribe phosphodiesterase type 5 inhibitors (PDE5i) for men who experience condom-associated erection difficulties with a view to increasing condom use and reducing risk of sexually transmitted infections.
Aim.? To examine whether the prevalence of erection-related condom problems differs between men using and not using PDE5i at the last condom-protected penile–vaginal (PVI) or penile–anal intercourse.
Methods.? Seven hundred-five men who had used a male condom during the past 3 months for PVI were selected from a sample recruited through advertisement to an electronic mailing list for a large, internet-based, sexual-enhancement product company. An internet-based questionnaire posted in 2006 assessed condom-use errors and problems.
Main Outcome Measures.? Men who did and did not use PDE5i during the last time a condom was used were compared on: (i) erection loss while applying a condom; (ii) erection loss during sex while using a condom; (iii) condom slipped off during sex; (iv) delayed condom application (penetration of the vagina or anus prior to application of the male condom); (v) early condom removal (condom taken off and intercourse continued without it); (vi) “problem with the way the condom fit”; (vii) “problem with the way the condom felt”; and (viii) condom breakage.
Results.? Controlling for age, marital status (yes/no), and having children (yes/no), PDE5i users, compared with nonusers, were: (i) three times more likely to report erection loss during sex while using a condom (adjusted odds ratio [AOR] = 3.21, 95% confidence interval [CI] = 1.40–7.39, P = 0.006); (ii) almost five times more likely to report the condom slipped off during sex (AOR = 4.75, 95% CI = 1.68–13.44, P = 0.003); and (iii) more than twice as likely to remove condoms before sex was over (AOR = 2.46, 95% CI = 1.09–5.56, P = 0.03).
Conclusions.? Physicians prescribing PDE5i may want to evaluate whether men are experiencing condom-associated erection difficulties and, if they are, consider titrating dosages and/or making referrals for psychosexual therapy and/or condom skills education.
1451-1456
Sanders, Stephanie A.
bb4ce9a1-0d94-4fe9-9113-f2ac41ec7961
Milhausen, Robin R.
34cc6d84-7ab0-49a0-a3ac-054ed9b6129f
Crosby, Richard A.
626c2897-4a0d-447c-8a82-b4068006646c
Graham, Cynthia A.
ac400331-f231-4449-a69b-ec9a477224c8
Yarber, William L.
2bf2b5cc-004a-4c27-9e88-039b532e22cf
2009
Sanders, Stephanie A.
bb4ce9a1-0d94-4fe9-9113-f2ac41ec7961
Milhausen, Robin R.
34cc6d84-7ab0-49a0-a3ac-054ed9b6129f
Crosby, Richard A.
626c2897-4a0d-447c-8a82-b4068006646c
Graham, Cynthia A.
ac400331-f231-4449-a69b-ec9a477224c8
Yarber, William L.
2bf2b5cc-004a-4c27-9e88-039b532e22cf
Sanders, Stephanie A., Milhausen, Robin R., Crosby, Richard A., Graham, Cynthia A. and Yarber, William L.
(2009)
Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage?
The Journal of Sexual Medicine, 6 (5), .
(doi:10.1111/j.1743-6109.2009.01267.x).
Abstract
Introduction.? Some physicians prescribe phosphodiesterase type 5 inhibitors (PDE5i) for men who experience condom-associated erection difficulties with a view to increasing condom use and reducing risk of sexually transmitted infections.
Aim.? To examine whether the prevalence of erection-related condom problems differs between men using and not using PDE5i at the last condom-protected penile–vaginal (PVI) or penile–anal intercourse.
Methods.? Seven hundred-five men who had used a male condom during the past 3 months for PVI were selected from a sample recruited through advertisement to an electronic mailing list for a large, internet-based, sexual-enhancement product company. An internet-based questionnaire posted in 2006 assessed condom-use errors and problems.
Main Outcome Measures.? Men who did and did not use PDE5i during the last time a condom was used were compared on: (i) erection loss while applying a condom; (ii) erection loss during sex while using a condom; (iii) condom slipped off during sex; (iv) delayed condom application (penetration of the vagina or anus prior to application of the male condom); (v) early condom removal (condom taken off and intercourse continued without it); (vi) “problem with the way the condom fit”; (vii) “problem with the way the condom felt”; and (viii) condom breakage.
Results.? Controlling for age, marital status (yes/no), and having children (yes/no), PDE5i users, compared with nonusers, were: (i) three times more likely to report erection loss during sex while using a condom (adjusted odds ratio [AOR] = 3.21, 95% confidence interval [CI] = 1.40–7.39, P = 0.006); (ii) almost five times more likely to report the condom slipped off during sex (AOR = 4.75, 95% CI = 1.68–13.44, P = 0.003); and (iii) more than twice as likely to remove condoms before sex was over (AOR = 2.46, 95% CI = 1.09–5.56, P = 0.03).
Conclusions.? Physicians prescribing PDE5i may want to evaluate whether men are experiencing condom-associated erection difficulties and, if they are, consider titrating dosages and/or making referrals for psychosexual therapy and/or condom skills education.
Text
PDFJSM24SeptFinal.pdf
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
More information
Published date: 2009
Organisations:
Psychology
Identifiers
Local EPrints ID: 206731
URI: http://eprints.soton.ac.uk/id/eprint/206731
ISSN: 1743-6095
PURE UUID: 11bc7496-cdd9-426d-a810-95ff172f4526
Catalogue record
Date deposited: 10 Jan 2012 17:12
Last modified: 21 Mar 2024 02:47
Export record
Altmetrics
Contributors
Author:
Stephanie A. Sanders
Author:
Robin R. Milhausen
Author:
Richard A. Crosby
Author:
William L. Yarber
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics